TLDR
- French pharmaceutical company Servier will acquire Day One Biopharmaceuticals (DAWN) at $21.50 per share in a transaction valued at roughly $2.5 billion
- The purchase price delivers a ~68% premium over Thursday’s closing price and represents an 86% premium to the 30-day VWAP
- DAWN shares jumped approximately 66% during premarket hours on March 6, 2026, after the acquisition announcement
- Day One’s board of directors has unanimously endorsed the transaction and advises shareholders to tender their shares
- Deal completion is anticipated in the second quarter of 2026, contingent on regulatory approval and majority shareholder acceptance
French pharmaceutical company Servier has reached an agreement to purchase Day One Biopharmaceuticals (DAWN) in a deal valued at approximately $2.5 billion, paid entirely in cash. The announcement triggered a sharp 66% climb in DAWN’s share price during Friday morning’s premarket session on March 6.
https://x.com/FenwickWest/status/2029944210065969265?s=20
Servier’s offer stands at $21.50 for each outstanding Day One share. This represents a 68% markup compared to Thursday’s final trading price and shows an 86% premium relative to the company’s 30-day volume-weighted average price.
Day One Biopharmaceuticals, Inc., DAWN
The transaction doesn’t include a financing contingency, eliminating a typical hurdle that can scuttle merger agreements. Completion is targeted for Q2 2026, subject to U.S. antitrust regulatory approval and a majority of Day One shareholders tendering their holdings.
Day One’s board of directors evaluated the proposal and unanimously voted to advise shareholders to accept the tender offer. Standard no-shop provisions are part of the agreement, along with an $87.7 million termination fee payable under specific circumstances if the transaction fails to consummate.
The deal wasn’t entirely unexpected. DAWN shares had already climbed Wednesday after media reports surfaced regarding potential takeover interest, with Jazz Pharmaceuticals (JAZZ) and Ipsen (IPSEY) mentioned as possible bidders at that time.
What Servier Gets
Servier’s primary acquisition target is tovorafenib, Day One’s flagship drug candidate designed to treat low-grade glioma — a brain tumor variant. The therapy holds significant promise in pediatric oncology, which represents the core focus of Day One’s development pipeline.
For Servier, this acquisition bolsters its rare oncology portfolio. The French pharmaceutical group, which generated €6.9 billion in revenue during fiscal year 2024/25, currently reinvests nearly 20% of its branded product revenue into research and development. Incorporating Day One’s portfolio aligns with Servier’s strategic objective to strengthen its position in precision cancer treatments.
Deal Structure
The acquisition follows an all-cash tender offer framework, with a subsequent merger completing once all requirements are satisfied. Servier’s ability to proceed without securing additional financing is viewed as increasing deal certainty.
The $87.7 million termination fee offers Day One some financial protection should the acquisition fail to materialize under specific scenarios.
Before this announcement, Wall Street analysts had set a price target of $17.00 per share on DAWN with a Buy rating — considerably lower than the $21.50 acquisition price.
DAWN’s market capitalization before the deal announcement was approximately $1.35 billion. The $2.5 billion transaction value highlights the substantial premium Servier is willing to pay to secure the company’s pipeline assets.
Day One operates from its headquarters in Brisbane, California. Upon completion, the acquisition will transfer complete ownership to Servier, a privately-held French pharmaceutical group that distributes medicines across more than 130 countries worldwide.
